US Stock MarketDetailed Quotes
CRVO CervoMed
- 10.490
- -0.310-2.87%
Close Dec 2 16:00 ET
86.58MMarket Cap-7249P/E (TTM)
12.830High9.770Low280.54KVolume12.720Open10.800Pre Close3.06MTurnover6.87%Turnover RatioLossP/E (Static)8.25MShares26.37952wk High1.90P/B42.82MFloat Cap5.85052wk Low--Dividend TTM4.08MShs Float3375000000.000Historical High--Div YieldTTM28.33%Amplitude4.140Historical Low10.907Avg Price1Lot Size
CervoMed Stock Forum
Sign in to post a comment
Its Friday with shorter trading time. Sleepy already. Some will run and some will get delayed market reaction.
$Applied Therapeutics (APLT.US)$ Crashed after FDA CRL but will resubmit. Dropped from 10 to 1.3 rebounded to 1.95. SI 16%
$PainReform (PRFX.US)$ Microfloat. Up after hours. SI 20%. 0 shares LTB. CTB 436%. If there is no catalyst, microfloats will be a quick play.✔️
$Blue Ocean Acquisition Corp (BOCN.US)$ Merger ...
$Applied Therapeutics (APLT.US)$ Crashed after FDA CRL but will resubmit. Dropped from 10 to 1.3 rebounded to 1.95. SI 16%
$PainReform (PRFX.US)$ Microfloat. Up after hours. SI 20%. 0 shares LTB. CTB 436%. If there is no catalyst, microfloats will be a quick play.✔️
$Blue Ocean Acquisition Corp (BOCN.US)$ Merger ...
51
13
7
$CervoMed (CRVO.US)$
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
CervoMed (NASDAQ: CRVO) announced that its oral drug neflamapimod received Orphan Drug Designation from the FDA for treating frontotemporal dementia (FTD).
The designation applies to therapies for rare diseases affecting fewer than 200,000 people in the US and provides benefits including tax credits, development assistance,...
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
CervoMed (NASDAQ: CRVO) announced that its oral drug neflamapimod received Orphan Drug Designation from the FDA for treating frontotemporal dementia (FTD).
The designation applies to therapies for rare diseases affecting fewer than 200,000 people in the US and provides benefits including tax credits, development assistance,...
3
$CervoMed (CRVO.US)$ Reuters· 2 mins ago
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
2
$CervoMed (CRVO.US)$ finally some volume again.
$CervoMed (CRVO.US)$ Suspension due to volatility. Maybe a slight rebound today?
$CervoMed (CRVO.US)$ this red bar looks too exaggerating to be true. merger is big news, I expect some recovery soon
1
$CervoMed (CRVO.US)$ no show?😓
1
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
73264095 : Nice, thanks! You think UMAC is done? looked like it held up pretty well in AH
Jaguar8 OP 73264095 : Nope. I feel it will still go
Jaguar8 OP 73264095 : I have not yet finished the list
Huaw : Will the rejection of APLT approval cause such a significant decline? Is it this serious?
Jaguar8 OP Huaw : It was just a CRL meaning they can’t approve at the moment due to some deficiencies which the company will address and will resubmit
View more comments...